LJPC 501

Drug Profile

LJPC 501

Alternative Names: LJPC-501; Synthetic angiotensin II - La Jolla

Latest Information Update: 10 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Neuropeptides; Oligopeptides; Peptide hormones; Vasoconstrictors
  • Mechanism of Action Angiotensin receptor agonists; Sodium-hydrogen antiporter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypotension
  • Discontinued Hepatorenal syndrome

Most Recent Events

  • 08 Aug 2017 La Jolla Pharmaceutical initiates Expanded access programme for the treatment of patients with catecholamine resistant Hypotension, in the US
  • 27 Feb 2017 La Jolla Pharmaceutical announces intention to submit NDA to the US FDA in second half of 2017
  • 27 Feb 2017 Positive top-line efficacy and adverse events data from the phase III ATHOS-3 trial in Hypotension released by La Jolla Pharmaceutical Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top